NuCana PLC
NCNA3.560USD
+0.090+2.59%
收盤 12/19, 16:00（美東）報價延遲15分鐘
5.11B總市值
0.01本益比TTM
關於 NuCana PLC 公司
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
NuCana PLC簡介
公司代碼NCNA
公司名稱NuCana PLC
上市日期Sep 28, 2017
CEO- -
員工數量20
證券類型Depository Receipt
年結日Sep 28
公司地址Lochside House
城市EDINBURGH
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United Kingdom
郵編EH12 9DT
電話4401313571111
網址https://www.nucana.com/
公司代碼NCNA
上市日期Sep 28, 2017
CEO- -
NuCana PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
+16.67%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
+300.00%
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Ian Webster
Mr. Ian Webster
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
+16.67%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
+300.00%
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 12月17日 週三
更新時間: 12月17日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Abingworth Management Limited
1.86%
Glass Jacobson Wealth Advisors
0.21%
Jane Street Capital, L.L.C.
0.18%
UBS Financial Services, Inc.
0.14%
Global Retirement Partners, LLC
0.06%
其他
97.55%
持股股東
持股股東
佔比
Abingworth Management Limited
1.86%
Glass Jacobson Wealth Advisors
0.21%
Jane Street Capital, L.L.C.
0.18%
UBS Financial Services, Inc.
0.14%
Global Retirement Partners, LLC
0.06%
其他
97.55%
股東類型
持股股東
佔比
Venture Capital
1.87%
Investment Advisor
0.42%
Research Firm
0.18%
Hedge Fund
0.02%
其他
97.52%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
49
156.10K
8.18%
+152.88K
2025Q2
52
554.99K
0.15%
+48.75K
2025Q1
52
492.36K
2.30%
-26.46K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Abingworth Management Limited
667.00
0.04%
--
--
Jun 30, 2025
Glass Jacobson Wealth Advisors
75.00
0%
--
--
Jun 30, 2025
Sofinnova Investments, Inc
998.00
0.05%
+998.00
--
Feb 14, 2025
Rhumbline Advisers Ltd. Partnership
40.00
0%
+31.00
+344.44%
Jun 30, 2025
Griffith (Hugh S)
53.00
0%
--
--
Dec 31, 2024
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jul 11, 2025
Merger
200→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
公告日期
類型
比率
Jul 11, 2025
Merger
200→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
常見問題
NuCana PLC的前五大股東是誰？
NuCana PLC的前五大股東如下：
Abingworth Management Limited持有股份：667.00佔總股份比例：0.04%。
Glass Jacobson Wealth Advisors持有股份：75.00佔總股份比例：0.00%。
Sofinnova Investments, Inc持有股份：998.00佔總股份比例：0.05%。
Rhumbline Advisers Ltd. Partnership持有股份：40.00佔總股份比例：0.00%。
Griffith (Hugh S)持有股份：53.00佔總股份比例：0.00%。
Abingworth Management Limited持有股份：667.00佔總股份比例：0.04%。
Glass Jacobson Wealth Advisors持有股份：75.00佔總股份比例：0.00%。
Sofinnova Investments, Inc持有股份：998.00佔總股份比例：0.05%。
Rhumbline Advisers Ltd. Partnership持有股份：40.00佔總股份比例：0.00%。
Griffith (Hugh S)持有股份：53.00佔總股份比例：0.00%。
NuCana PLC的前三大股東類型是什麼？
NuCana PLC 的前三大股東類型分別是：
Abingworth Management Limited
Glass Jacobson Wealth Advisors
Jane Street Capital, L.L.C.
Abingworth Management Limited
Glass Jacobson Wealth Advisors
Jane Street Capital, L.L.C.
有多少機構持有NuCana PLC(NCNA)的股份？
截至2025Q3，共有49家機構持有NuCana PLC的股份，合計持有的股份價值約為156.10K，占公司總股份的8.18% 。與2025Q2相比，機構持股有所增加，增幅為8.04%。
哪個業務部門對NuCana PLC的收入貢獻最大？
在--，--業務部門對NuCana PLC的收入貢獻最大，創收--，占總收入的--% 。
